Covered recipient · General Payments record
ALEXANDER KW MAYBACH
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2025
$317.06
- Reported across 14 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2025 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $317.06 | 14 |
By paying entity
PY2025 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GlaxoSmithKline, LLC. | $58.30 | 3 |
| Exact Sciences Corporation | $56.77 | 2 |
| DEXCOM, INC. | $31.47 | 1 |
| Acerta Pharma LLC | $27.71 | 1 |
| Gilead Sciences, Inc. | $25.19 | 1 |
| PFIZER INC. | $24.01 | 1 |
| ABBVIE INC. | $23.27 | 1 |
| Novo Nordisk AS | $19.20 | 1 |
| Merck Sharp & Dohme Corporation | $18.93 | 1 |
| Amgen Inc. | $17.95 | 1 |
| Currax Pharmaceuticals LLC | $14.26 | 1 |
By program year
All program years on this page · sorted by year
| Program year | Amount | Records |
|---|---|---|
| PY2025 | $317.06 | 14 |
Payment records · PY2025 (14)
Ordering applied by this site (paying entity, then date) · record values are shown as CMS published them
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $23.27 | 04/09/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1203039928 | CMS |
| Amgen Inc. | $17.95 | 12/23/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1228333699 | CMS |
| AstraZeneca Pharmaceuticals LP | $27.71 | 03/11/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1206399946 | CMS |
| Currax Pharmaceuticals LLC | $14.26 | 06/24/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1242700742 | CMS |
| Dexcom, Inc. | $31.47 | 12/11/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1250467289 | CMS |
| Exact Sciences Corporation | $29.33 | 02/25/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1235398818 | CMS |
| Exact Sciences Corporation | $27.44 | 05/14/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1235398822 | CMS |
| Gilead Sciences, Inc. | $25.19 | 11/25/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1234472698 | CMS |
| GlaxoSmithKline, LLC. | $19.95 | 04/29/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1190587655 | CMS |
| GlaxoSmithKline, LLC. | $16.54 | 09/04/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1191773577 | CMS |
| GlaxoSmithKline, LLC. | $21.81 | 10/21/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1190374831 | CMS |
| Merck Sharp & Dohme LLC | $18.93 | 08/06/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1238179739 | CMS |
| Novo Nordisk Inc | $19.20 | 12/04/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188979859 | CMS |
| PFIZER INC. | $24.01 | 01/28/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1230032308 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2025
- Source files
- Dataset page · Bulk file · PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.